Discover Ways to Save on VesCell
We're working hard to make sure you have every possible option to afford therapy.
100% Satisfaction Guarantee:
We stand behind every VesCell treatment.
If you’re not satisfied with your results, you can receive a full refund—or a second treatment at no cost if clinical outcomes are not met. This reflects our confidence in VesCell’s ability to transform lives and our commitment to your peace of mind throughout your treatment journey.
More than just savings, we'll help you navigate the end to end care process to ensure you stay on track with your treatment plan.
Dedicated 1-to-1 support. To help you navigate your insurance, payment options and answer your questions about your personalized care.
Payment Plans. Our goal is to help you match your current expenses with convenient and comfortable monthly payments.
Chart and Lab Reviews. To help you Decide if Vescel is right for you, we offer a range of diagnostic services includes: MRI/CAT Scan, Medical Chart, Cognitive Tests and others. Submit your most recent scans (within the last year), and our Board Certified Physicians will evaluate them. We’ll order additional testing to help you decide if VesCell is right for you.
Speak with a Savings Specialist
Using your Savings Options
Our Savings Experts can help navigate your unique situation. All programs come with flexible financing options.
-
Premium Concierge Treatment Package
Experience world-class care with our full cash pay option for VesCell therapy offered at premier offshore clinics. This exclusive package includes high-end concierge clinical services, personalized support from a US Board-Certified physician, and comprehensive travel assistance to ensure a seamless treatment journey. -
Premium Patient-Funded Clinical Study
Join a patient-funded clinical study for VesCell therapy, conducted in the US and at world-class offshore clinics, and receive unparalleled care with high-end concierge clinical services, personalized oversight from a US Board-Certified physician, and comprehensive travel support for a seamless, premium experience. -
US-Based "Right to Try" Compassionate Use
Access VesCell therapy through our US-based "Right to Try" option, available at our premier US clinics. This exclusive package includes FDA case-by-case filing, ethics approval for compassionate use, personalized care from a US Board-Certified physician, and comprehensive concierge services to ensure a seamless, high-end treatment experience.
Realizing your full potential
As we age, the burden of cardiovascular and cognitive disease will increase pressure on healthcare resources. Therapies that can improve quality of life, reduce hospitalization, delay surgeries, and diminish the requirement for long-term care offer systemic sustainability in addition to clinical benefit. Stem Cells are positioned to play a central role in this landscape.
Important Safety Data
- VesCell (ACP-01) is an investigational therapy under development, not approved by the FDA, and only available in specific countries.
- Treatments are subject to health regulations in Canada, Bahamas, Dominican Republic, and Switzerland, and not US FDA oversite.
- Canada’s Special Access program allows unapproved treatments for serious conditions when conventional therapies have failed.
- U.S. Patients travel at their own risk for treatments received abroad.
- US Patients should consult with their physicians before seeking treatment abroad.
- Treatments are generally out of pocket expenses and may not be covered by US insurance.
Treatment Risk Information
Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data
Fraser C Henderson*, Ina Sarel, Kelly Tuchman, Stephen Lewis and York Hsiang
Volume5-Issue2
Dates: Received: 2024-01-18 | Accepted: 2024-02-01 | Published: 2024-02-02
Pages: 092-105
Abstract
Introduction: Critical limb ischemia has a prevalence in the US of 1.33%, with mortality 15-20% and major amputation 10-40% per year. Stem cell treatment has emerged as a treatment option for the 45% of patients for whom revascularization procedures are not possible.
Objective: This study re-examines the data of the Phase II clinical treatment of no option Critical limb ischemia with Hemostemix’ angiogenic cell precursors, focusing upon ulcer wound healing, amputation and death rate of this cohort.
Methods: Primary endpoints were changes in ulcer size and major amputation or death within one year of treatment. The secondary endpoint was change in pain level.
Results: From 2015 to 2021, 67 patients with no option Critical limb ischemia were allocated to treatment with ACP-01 (46/67) or placebo (21/67). From this data, only patients who presented with wound ulcers before administration of ACP-01 were reviewed (21 treatment, 8 placebo). Ulcer size in the treated group decreased from a mean of 1.46 cm2 to 0.48 mm2 (p = 0.01) by 3 months. There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%). Change in pain was not significant in either group at 3 months, but at 1 year was improved in the placebo group (p = 0.01).
Conclusion: The administration of ACP-01 within a program of careful patient follow up is safe and associated with reduced ulcer size and decreased rate of amputation and death. Consideration should be given to re-administration of stem cell treatments every 3-6 months to optimize improvement of Critical limb ischemia. Further studies, more appropriately powered, are warranted.